Elevated level of serum cystatin-C concentration is a useful predictor for myelosuppression induced by methotrexate for treatment of rheumatoid arthritis

References

• Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM, Mielants H, MUller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating sys-tematic literature research and expert opinion of a broad inter-national panel of rheumatologists in the 3E initiative. Ann Rheum Dis. 2009;68: 1086–93.
   Google Scholar
• Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1985;12(Suppl 12):35–9.
   Google Scholar
• Proper use information for rheumatrex, vol. 15. Wyeth Corpo-ration; 2009. p. 4.
   Google Scholar
• Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancyto-penia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44: 1051–5.
   Google Scholar
• Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989;32:1592–6.
   PubMed Web of Science ®Google Scholar
• al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheu-matol. 1993;20:1121–5.
   Google Scholar
• Boey O, Van Hooland S, Woestenburg A, Van der Niepen P, Verbeelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg. 2006;61:166–9.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in South Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol. 2005;16:1413–9.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Rothenbacher D. Prevalence of chronic kidney dis-ease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100–4.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004;34:465–83.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833–41.
   Google Scholar
• Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160:622–8.
   PubMed Web of Science ®Google Scholar
• Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005;52:3030–8.
   Google Scholar
• Gutierrez-Urefia S, Molina JF, Garcia CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheu-matoid arthritis. Arthritis Rheum. 1996;39:272–6.
   PubMedGoogle Scholar
• Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of metho-trexate in rheumatoid arthritis. J Rheumatol. 1995;22:218–23.
   PubMed Web of Science ®Google Scholar
• Coleiro B, Mallia C. Toxicity profile of methotrexate in rheu-matoid arthritis. A preliminary study. Adv Exp Med Biol. 1999;455:359–65.
   PubMedGoogle Scholar
• Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20: 639–44.
   Google Scholar
• Freeman MV. The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man. J Pharmacol Exp Ther. 1958;122:154–62.
   PubMedGoogle Scholar
• Chlanek J, Martinková J, Simková M, Vanecková J, Koudelková V, Nozicková M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998;53:437–44.
   PubMedGoogle Scholar
• Chlanek J, Grim J, Martinková J, Simková M, Vanièková J, Koudelková V, Noièková M. Pharmacokinetics and pharmaco-dynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54:147–56.
   Google Scholar
• Bressolle F, Bologna C, Edno L, Bernard JC, Gomeni R, Sony J, Combe B. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol. 1996;49:285–92.
   Google Scholar
• Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S. Methotrexate kinetics in rheumatoid arthritis: is there an inter-action with nonsteroidal antiinfiammatory drugs? J Rheumatol. 1988;15:1356–60.
   Google Scholar
• Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667–72.
   Google Scholar
• Bressolle F, Bologna C, Kinowski JM, Sony J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of metho-trexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57:110–3.
   Google Scholar
• Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004;41:467–550.
   PubMed Web of Science ®Google Scholar
• White C, Akbari A, Hussain N, Dinh L, Filler G, Lepage N, Knoll GA. Estimating glomerular filtration rate in kidney transplanta-tion: a comparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol. 2005;16:3763–70.
   Google Scholar
• Maillard N, Mariat C, Bonneau C, Mehdi M, Thibaudin L, Laporte S, Alamartine E, Chamson A, Berthoux F. Cystatin C-based equa-tions in renal transplantation: moving toward a better glomerular filtration rate prediction? Transplantation. 2008;85:1855–8.
   Google Scholar
• Shlipak MG, Katz R, Kestenbaum B, Fried LF, Newman AB, Siscovick DS, Stevens L, Sarnak MJ. Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol. 2009;30:171–8.
   PubMedGoogle Scholar
• Shoda H, Inokuma S, Yajima N, Tanaka Y, Oobayashi T, Setoguchi K. Higher maximal serum concentration of metho-trexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients. Mod Rheumatol. 2007;17:311–6.
   PubMedGoogle Scholar
• Alarck GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, St Clair EW, Sundy JS, Alexander RW, Smith GJ, Axiotis CA. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127 :356–64.
   Google Scholar